Research

Hormonal

Once-weekly subcutaneous semaglutide 2.4 mg, used as an adjunct to lifestyle intervention, significantly reduces the 10-year risk of developing type 2 diabetes in adults with overweight or obesity compared to placebo.

If you have obesity or overweight with related health issues, adding once-weekly semaglutide 2.4 mg to your lifestyle changes can significantly lower your 10-year risk of developing type 2 diabetes compared to lifestyle changes alone. This benefit is most pronounced in those with higher baseline risk or prediabetes, and maintaining the treatment appears necessary to sustain these lower risk scores.

GoodSupportsHIGH confidence
This analysis suggests that semaglutide 2.4 mg as an adjunct to lifestyle intervention may lower the risk of developing T2D in people with overweight (with weight-related comorbidities) or obesity, particularly in those individuals with high CMDS scores at baseline.
Lua Wilkinson et al. · Obesity · 2023

Why this rating

Based on post hoc analysis of three large, randomized, double-blind, placebo-controlled phase 3 trials (STEP 1, 4, 5) with rigorous statistical modeling (CMDS).

Source

Effect of semaglutide 2.4 mg once weekly on 10‐year type 2 diabetes risk in adults with overweight or obesity

Lua Wilkinson et al. · Obesity · 2023

DOI 10.1002/oby.23842

rct · n=2654Cited 19×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →